Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors
R. K. Powers, K. D. Sullivan, R. Culp-Hill, M. P. Ludwig, K. P. Smith, K. A. Waugh, R. Minter, K. D. Tuttle, H. C. Lewis, A. L. Rachubinski, R. E. Granrath, R. B. Wilkerson, D. E. Kahn, M. Joshi, A. D'Alessandro, , J. M. Espinosa
This study identifies a mechanism by which Trisomy 21 increases kynurenine pathway activity through overexpression of interferon receptors, leading to immunosuppression and neurotoxicity in Down syndrome.
bioRxiv · Jan 11, 2019Physiology